Company Overview of Drais Pharmaceuticals, Inc.
Drais Pharmaceuticals, Inc. is a drug development company that focuses on early and mid-stage clinical development through proof of concept. Its pipeline of products include ASP3291, a cyclic peptide melanocortin receptor 1 agonist that is used for the treatment of ulcerative colitis; ASP7147, a small molecule bombesin-2 receptor antagonist to improve symptoms in patients with diarrhea-predominant irritable bowel syndrome; and ASP7035, a small molecule selective vasopressin 2 receptor agonist for the treatment of nocturia. Drais Pharmaceuticals, Inc. was founded in 2007 and is based in Bridgewater, New Jersey.
520 US Highway 22
Bridgewater, NJ 08807
Founded in 2007
Key Executives for Drais Pharmaceuticals, Inc.
Drais Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|Nanocopoeia, Inc.||United States|
|Asterand, Inc.||United States|
|Berkeley Advanced Biomaterials, Inc.||United States|
|Cypress Pharmaceutical, Inc.||United States|
|Active Nutrition||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Drais Pharmaceuticals, Inc., please visit www.draispharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.